Please use this identifier to cite or link to this item: http://hdl.handle.net/10637/15505
Full metadata record
DC FieldValueLanguage
dc.contributor.otherUCH. Departamento de Farmacia-
dc.creatorPablo, E. de-
dc.creatorO'Connell, Peter-
dc.creatorFernández García, Raquel-
dc.creatorMarchand, S.-
dc.creatorChauzy, A.-
dc.creatorTewes, F.-
dc.creatorDea Ayuela, María Auxiliadora-
dc.creatorKumar, D.-
dc.creatorBolás Fernández, Francisco-
dc.creatorBallesteros, M. P.-
dc.creatorTorrado Durán, Juan José-
dc.creatorHealy, Anne Marie-
dc.creatorSerrano López, Dolores Remedios-
dc.date.accessioned2024-02-28T13:13:24Z-
dc.date.available2024-02-28T13:13:24Z-
dc.date.issued2023-03-25-
dc.identifier.citationDe Pablo, E., O'Connell, P., Fernández-García, R., Marchand, S., Chauzy, A., Tewes, F., Dea-Ayuela, M.A., Kumar, D., Bolás, F., Ballesteros, M.P., Torrado, J.J., Healy, A.M. & Serrano, D.R. (2023). Targeting lung macrophages for fungal and parasitic pulmonary infections with innovative amphotericin B dry powder inhalers. International Journal of Pharmaceutics, vol. 635, art. 122788. DOI: https://doi.org/10.1016/j.ijpharm.2023.122788es_ES
dc.identifier.issn0378-5173-
dc.identifier.urihttp://hdl.handle.net/10637/15505-
dc.description.abstractThe incidence of fungal pulmonary infections is known to be on the increase, and yet there is an alarming gap in terms of marketed antifungal therapies that are available for pulmonary administration. Amphotericin B (AmB) is a highly efficient broad-spectrum antifungal only marketed as an intravenous formulation. Based on the lack of effective antifungal and antiparasitic pulmonary treatments, the aim of this study was to develop a carbohydrate-based AmB dry powder inhaler (DPI) formulation, prepared by spray drying. Amorphous AmB microparticles were developed by combining 39.7 % AmB with 39.7 % γ-cyclodextrin, 8.1 % mannose and 12.5 % leucine. An increase in the mannose concentration from 8.1 to 29.8 %, led to partial drug crystallisation. Both formulations showed good in vitro lung deposition characteristics (80 % FPF < 5 µm and MMAD < 3 µm) at different air flow rates (60 and 30 L/min) when used with a DPI, but also during nebulisation upon reconstitution in water.es_ES
dc.language.isoenes_ES
dc.publisherElsevieres_ES
dc.relationEste artículo de investigación ha sido financiado parcialmente por la Universidad Complutense de Madrid y por la Science Foundation Ireland a través del Fondo Europeo de Desarrollo Regional (SFI/12/RC/2275 y SFI/12/RC/). También, ha sido financiado por el Ministerio de Ciencia e Innovación del Gobierno de España (PID2021-126310OA-I00).-
dc.relationPID2021-126310OA-I00-
dc.relation.ispartofInternational Journal of Pharmaceutics, vol. 635-
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.es-
dc.rightsOpen Access-
dc.subjectAerosoleses_ES
dc.subjectAerosol therapyes_ES
dc.subjectUso terapéuticoes_ES
dc.subjectTherapeutic usees_ES
dc.subjectPulmoneses_ES
dc.subjectLungses_ES
dc.subjectEnfermedades_ES
dc.subjectDiseaseses_ES
dc.subjectMicrobiología farmacéuticaes_ES
dc.subjectPharmaceutical microbiologyes_ES
dc.titleTargeting lung macrophages for fungal and parasitic pulmonary infections with innovative amphotericin B dry powder inhalerses_ES
dc.typeArtículoes_ES
dc.identifier.doihttps://doi.org/10.1016/j.ijpharm.2023.122788-
dc.relation.projectIDSFI/12/RC/2275-
dc.relation.projectIDSFI/12/RC/-
dc.centroUniversidad Cardenal Herrera-CEU-
Appears in Collections:Dpto. Farmacia




Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.